Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06657768 | A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | PHASE1 | RECRUITING | 128 | — | — | Oct 29, 2024 | Jul 1, 2027 | Jun 4, 2026 | 13 | United States, Japan |
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4006895 of Part A (SAD) | EXPERIMENTAL | Single-ascending doses of LY4006895 administered intravenously (IV) |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4006895 of Part B (MAD) | EXPERIMENTAL | Multiple-ascending doses of LY4006895 will be administered IV |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4006895 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria for Part A and Part B: \- Have a body mass index (BMI) within the range 18 to 40 kilogram per square meter (kg/m²) For Part A: * Are overtly healthy as determined by medical evaluation. Rescreening is not allowed in this study For Part B: * Have early symptomatic AD, as defin...